Brief: Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy
09/03/2026 21:34
March 9 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O: VERTEX ANNOUNCES POSITIVE WEEK 36 INTERIM ANALYSIS RESULTS FOR PRIMARY AND ALL SECONDARY ENDPOINTS IN THE RAINIER PHASE 3 TRIAL OF POVETACICEPT IN ADULTS WITH IGA NEPHROPATHY VERTEX PHARMACEUTICALS INC - TO COMPLETE BLA FOR POVETACICEPT BY END OF MARCH FOR POTENTIAL U.S. ACCELERATED APPROVAL VERTEX PHARMACEUTICALS: POVETACICEPT WAS GENERALLY SAFE AND WELL TOLERATED Source text: ID:nBw2NCH39a Further company coverage: VRTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vertex Pharmaceuticals
See all newsBrief: Vertex Announces US FDA Acceptance Of Biologics License Application For Accelerated Approval Of Povetacicept In IgA Nephropathy
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings
Vertex Q1 adjusted EPS beats estimates, revenue rises 8%
Vertex tops profit estimates as sales of new cystic fibrosis drug surge
Brief: Vertex Pharmaceuticals Q1 Adjusted EPS USD 4.47 Vs. IBES Estimate USD 4.31